Sarah Bos

33 Hemostatic profiles are similar across all etiologies of cirrhosis. 2 References 1. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365(2):147-156. 2. Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease : evidence and clinical consequences. Blood. 2010;116(6):878-885. 3. Lisman T, Bongers TN, Adelmeijer J, et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology. 2006;44(1):53-61. 4. Hernández Conde M, Llop Herrera E, de la Revilla Negro J, et al. Prevalence and outcome of portal thrombosis in a cohort of cirrhotic patients undergoing liver transplantation. Arthritis Care Res. 2016;108(11):716-720. 5. Aldawood A, Arabi Y, Aljumah A, et al. The incidence of venous thromboembolism and practice of deep venous thrombosis prophylaxis in hospitalized cirrhotic patients. Thromb J. 2011;9(1):1. 6. Groeneveld D, Porte RJ, Lisman T. Thrombomodulin-modified thrombin generation testing detects a hypercoagulable state in patients with cirrhosis regardless of the exact experimental conditions. Thromb Res. 2014;134(3):753-756. 7. Tripodi A, Salerno F, Chantarangkul V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology. 2005;41(3):553- 558. 8. Gatt A, Riddell A, Calvaruso V, Tuddenham EG, Makris M, Burroughs AK. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost. 2010;8(9):1994-2000. 9. Kleinegris MC, Habets CAM, Van De Sande AJP, et al. Liver cirrhosis is associated with hypercoagulability, decreased clot strength and normal fibrinolysis. J Thromb Haemost. 2013;11(May):49-50. 10. Vinholt PJ, Alnor AB, Nybo M, Hvas A-M. The primary hemostasis is more preserved in thrombocytopenic patients with liver cirrhosis than cancer. Blood Coagul Fibrinolysis. 2018;(29):307/313. 11. Krzanicki D, Sugavanam A, Mallett S. Intraoperative hypercoagulability during liver transplantation as demonstrated by thromboelastography. Liver Transplant. 2013;19(8): 852-861. 12. Pihusch M, Hiller E, Beuers U, Pihusch R, Rank A, Go P. Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease. 2002;37:548-555. 13. Ben-Ari Z, Panagou M, Patch D, et al. Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography. J Hepatol. 1997;26(3):554-559. 14. Hugenholtz GCG, Lisman T, Stravitz RT. Thromboelastography does not predict outcome in different etiologies of cirrhosis. Res Pract Thromb Haemost. 2017;1(2):275-285. 15. Potze W, Siddiqui MS, Boyett SL, et al. Preserved hemostatic status in patients with non- alcoholic fatty liver disease. J Hepatol. 2016;65(5):980-987.